ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1595

Genome-Wide Association Study to High -Throughput Cell-Based Phenotypic Screen Identifies Novel Chemical Inhibitors of CD40 Signaling

Gang Li1, Dorothee Diogo2, Di Wu1, Jim Spoonamore3, Rheumatoid Arthritis Consortium International (RACI)4, Eli Stahl5, Nicola Tolliday3 and Robert M. Plenge6, 1Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women's Hospital, Boston, MA, 2Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 3Broad Institute, Cambridge, MA, 4Boston, 5Brigham and Women's Hospital, 6Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: B cells, drug therapy, genomics and rheumatoid arthritis, pathogenesis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Plenary Session II: Discovery 2012

Session Type: Plenary Sessions

Background/Purpose: Deriving therapeutic targets from human genetics linked with biological alterations of risk alleles may provide a more successful approach to drug development than traditional efforts that focus on biological insight alone.  Here, we successfully translate a SNP association from a genome-wide association study (GWAS) in rheumatoid arthritis (RA) into a high-throughput screen (HTS) based on cellular phenotype in a human B cell line to identify inhibitors of CD40-mediated NF-κB signaling. 

Methods: We fine-map the CD40 risk locus in 7,222 seropositive RA patients and 15,870 controls genotyped on the Immunochip, together with deep sequencing of CD40 coding exons in 500 RA cases and 650 controls. We use flow cytometry to measure CD40 protein levels on the surface of primary CD19+ from 90 healthy control individuals.  We use gene expression arrays to measure CD40 RNA levels in peripheral blood mononuclear cells from 1,469 healthy control individuals.  We use retroviral shRNA infection to perturb the amount of CD40 on the surface of a human B lymphocyte cell line (BL2). We develop a high-throughput NF-κB luciferase reporter assay in BL2 cells activated with trimerized CD40 ligand (tCD40L), and conduct an HTS of 1,982 chemical compounds and FDA-approved drugs. Counter-screens of the top “hit” compounds were performed in the BL2 line activated with both tCD40L and LPS, and in an additional B cell line, Ramos, activated with tCD40L and TNF.  Two known and two novel compounds were tested for inhibition of tCD40-NFkB signaling in primary human CD19+ B cells by measuring CD86 expression with flow cytometry.

Results: A single common SNP at the CD40 locus explains the entire signal of association (rs4810485, P=1.4×10-9), without any evidence for independent rare variants contributing to RA risk.  Subjects homozygous for the common RA risk allele have ~33% more CD40 on the surface of primary human CD19+ B lymphocytes than subjects homozygous for the non-risk allele (P=10-9), a finding corroborated by expression quantitative trait loci (eQTL) analysis in PBMC’s (P<10-15).  We observe a direct correlation between amount of CD40 protein and phosphorylation of RelA (p65), a subunit of the NF-κB transcription factor. Using our luciferase reporter assay, we identify 81 “hit” compounds (out of 1,982) that consistent inhibit luciferase activity following tCD40L activation.  After a series of counter-screens and testing in primary human CD19+ B cells, we identify 2 “known” and 2 “novel” chemical inhibitors not previously implicated in inflammation or CD40-mediated NF-κB signaling.  One known inhibitor is tranilast, a drug currently in a phase II clinical trial of RA; the other is a corticosteroid derivative.  The two novel compounds represent promising tool compounds to develop new therapies to treat RA.

Conclusion: Our study demonstrates proof-of-concept that human genetics can be used to guide the development of phenotype-based, high-throughput small-molecule screens to identify potential novel therapies in complex traits such as RA.


Disclosure:

G. Li,
None;

D. Diogo,
None;

D. Wu,
None;

J. Spoonamore,
None;

E. Stahl,
None;

N. Tolliday,
None;

R. M. Plenge,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genome-wide-association-study-to-high-throughput-cell-based-phenotypic-screen-identifies-novel-chemical-inhibitors-of-cd40-signaling/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology